Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: A practical guide for yttrium-90 microsphere liver-directed therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 2, 2010, Pages 233-236

  Wong, Ching Yee Oliver ^a   Gates, Vanessa L ^b   Tang, Bingfeng ^a   Campbell, Janice ^a   Qing, Feng ^a   Lewandowski, Robert J ^b   Thie, Joseph ^c   Ho, Chi Lai ^d   Savin, Michael ^a   Salem, Riad ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

^d Hong Kong Sanitorium and Hospital   (Hong Kong)

Author keywords

Extrahepatic metastatic potential; PET endpoint of tumor load reduction

Indexed keywords

ALBUMIN TC 99M; FLUORODEOXYGLUCOSE F 18; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; LIVER ANGIOGRAPHY; LIVER METABOLISM; LIVER METASTASIS; MALE; METASTASIS POTENTIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICROSPHERES; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; TUMOR CELLS, CULTURED; YTTRIUM RADIOISOTOPES;

EID: 77951972129     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0735     Document Type: Article

References (24)

1. Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13 (suppl 9) : S259.
2. Wong CY, Salem R, Raman S, et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: A comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002;29:815.
3. Drbe EM, Day DE. Chemical durability of Y2O3-Al2O3-SiO2 glasses for the in vivo delivery of beta radiation. J Biomed Mater Res 1993;27:1301.
4. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673.
5. Ho S, Lau WY, Leung TWT, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24:293.
6. 18F-FDG PET. J Nucl Med 2004;45:1892.
7. 18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005;16:1101.
8. Wong CO, Savin M, Qing F, et al. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy refractory metastatic liver carcinoma: A quantitative comparison of tumor response with glass and resin based agents. Cancer Biother Radiopharm 2006;21:305.
9. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213.
10. Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902.
11. ™) for the treatment of unresectable hepatocellular carcinoma (HCC) in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335.
12. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: Improved treatment with intraarterial yttrium-90. Radiology 1988;169:311.
13. Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust NZ J Surg 1992;62:105.
14. Wong CYO, Thie J, Parling-Lynch KJ, et al. Glucosenormalized standard uptake value (SUV) from F-18 FDG PET in classifying lymphomas. J Nucl Med 2005;46:1659.
15. Thie JA, Hubner KF, Smith GT. The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors. J Nucl Med 2000;41:1664.
16. 18F-FDG PET on managing patients with colorectal cancer: The referring physician's perspective. J Nucl Med 2001;42:586.
17. Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 2002;27:550.
18. Valk PE, Abella-columna E, Hasemann MK, et al. Whole body PET imaging with F-18 fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503.
19. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613.
20. Selzner M, Hany TF. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027.
21. Finkelstein SE, Fernandez FG, Dehdashti F, et al. Unique site-and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J Hepatobiliary Pancreat Surg 2008;15:483.
22. Barker DW, Zagoria RJ, Morton KA, et al. Evaluation of liver metastases after radiofrequency ablation: Utility of 18F-FDG PET and PET/CT. AJR 2005;184:1096.
23. Van Hazel G, Blackwell A, Anderson J, et al. Randomized phase 2 trail of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78.
24. Park KC, Schwimmer J, Shepherd JE, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001;233:310.